Print

Proteonomix, Inc. (PROT) Retains Numoda Corporation to Provide Clinical Trial Services for Phase 1 Trial With UMK-121 in End-Stage Liver Disease  
9/12/2012 10:10:01 AM

PARAMUS, N.J.--(BUSINESS WIRE)--Proteonomix, Inc. (OTCBB:PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, today announced that Numoda Corporation will provide a range of specific clinical trial services for a Proteonomix-sponsored Phase 1 clinical trial with its patent-pending mobilization technology UMK-121 in patients with end-stage liver disease (ESLD). Numoda is leading provider of clinical trial information and logistics services to life sciences companies.
//-->